Radium-223 and Radiotherapy in Hormone-Naïve Men With Oligometastatic Prostate Cancer to Bone
Status:
Active, not recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
This is a phase IIa, open label, single arm, and prospective study of hormone therapy-naïve
men with oligometastatic prostate cancer to the bone. The study will test if treating the
primary tumor sites and 5 or fewer sites of bone-only metastasis with external beam radiation
with concomitant systemic Radium-223 will reduce the utilization of androgen deprivation
therapy, improve QOL and improve OS over a the comparator cohort of SWOG intermittent ADT
historic cohort.